Premium
Tranexamic Acid for Upper Gastrointestinal Bleeding
Author(s) -
Beyda Raymond,
Johari Davood
Publication year - 2019
Publication title -
academic emergency medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.221
H-Index - 124
eISSN - 1553-2712
pISSN - 1069-6563
DOI - 10.1111/acem.13835
Subject(s) - medicine , tranexamic acid , upper gastrointestinal bleeding , gastrointestinal bleeding , lansoprazole , placebo , antifibrinolytic , aspirin , randomized controlled trial , adverse effect , number needed to treat , relative risk , omeprazole , anesthesia , surgery , endoscopy , confidence interval , blood loss , alternative medicine , pathology
Upper gastrointestinal bleeding is common and accounts for at least half of the nearly 500,000 annual U.S. hospitalizations for gastrointestinal bleeding.1 In the acute setting, severe bleeding is treated with intravenous fluids, blood products, antiulcer therapy, and hemostasis by endoscopy.2 Tranexamic acid (TXA) is an antifibrinolytic agent shown to reduce bleeding.3,4 TXA has been proven to be effective in improving patient-centered outcomes after severe hemorrhage due to trauma.5 The authors of this systematic review sought to evaluate the benefit of TXA administration specifically for upper gastrointestinal bleeding. This article is protected by copyright. All rights reserved.